New Breath Actuated MDI Symbicort Compared to Symbicort pMDI and Budesonide pMDI for 12 Weeks Twice a Day
Status:
Completed
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
This is a comparison of the efficacy of the Symbicort breath actuated dose inhaler to the
Symbicort pressured meter dose inhaler after 12 weeks of a twice a day dose.
Phase:
Phase 3
Details
Lead Sponsor:
AstraZeneca
Treatments:
Budesonide Budesonide, Formoterol Fumarate Drug Combination